Diagnosis, treatment and genetic analysis of a case of Alstrom syndrome caused by compoud heterozygous mutation of ALMS1
Received date: 2022-08-12
Revised date: 2022-09-30
Online published: 2022-10-14
Supported by
Support by Jiangsu Innovation Team Fund Project(CXTDC2016005)
Alstrom syndrome is a rare autosomal recessive disorder disease caused by mutations in the ALMS1 gene, and its typical clinical manifestations include cone-rod retinal dystrophy, sensorineural deafness, obesity, insulin resistance, diabetes mellitus, hypertriglyceridemia, non-alcoholic fatty liver, dilated cardiomyopathy, and progressive hepatic and renal dysfunction. In this report, we followed up a young male patient presenting with diabetes mellitus, who was later diagnosed with blindness, deafness, hyperlipidemia, obesity, fatty liver, and insulin resistance. Genetic testing revealed a compound heterozygous mutation in ALMS1 from the patient, with an exon 8 c.5535delG (p.S1847Lfs*24) mutation inherited from the maternal side and an exon 16 c.10819C>T (p.R3607X) mutation from the paternal side. Neither of these two mutations had been previously recorded in the known ALMS1 genetic mutation database. Hyperinsulinemic-euglycemic clamp test indicated that the insulin sensitivity index was significantly improved in the patient after taking oral dapagliflozin. By summarizing and analyzing this case, we should consider Alstrom syndrome in clinical adolescent-onset diabetes patients with blindness, deafness, severe insulin resistance, and lipid metabolism disorder. These two new mutation sites identified in this case enrich the genetic mutation database of the ALMS1 gene, and the follow-up data of this study provide new evidence for deciding appropriate glucose-lowering regimens in patients with Alstrom syndrome.
Key words： Alstrom syndrome; ALMS1; diabetes mellitus; blindness; sensorineural hearing loss
Huijie Yang, De Li, Huiling Bai, Ming Zhang, Jun Huang, Xiaoqing Yuan . Diagnosis, treatment and genetic analysis of a case of Alstrom syndrome caused by compoud heterozygous mutation of ALMS1[J]. Hereditas(Beijing), 2022 , 44(12) : 1148 -1157 . DOI: 10.16288/j.yczz.22-217
| [1] | Zhou C, Xiao YY, Xie HB, Liu SL, Wang J. A novel variant in ALMS1 in a patient with Alstr?m syndrome and prenatal diagnosis for the fetus in the family:a case report and literature review. Mol Med Rep, 2020, 22(4): 3271- 3276. |
| [2] | Marshall JD, Maffei P, Collin GB, Naggert JK. Alstr?m syndrome: genetics and clinical overview. Curr Genomics, 2011, 12(3): 225-235. |
| [3] | Zhang JJ, Wang JQ, Sun MQ, Xu D, Xiao Y, Lu WL, Dong ZY. Alstr?m syndrome with a novel mutation of ALMS1and Graves’ hyperthyroidism:a case report and review of the literature. World J Clin Cases, 2021, 9(13): 3200- 3211. |
| [4] | Shenje LT, Andersen P, Halushka MK, Lui C, Fernandez L, Collin GB, Amat-Alarcon N, Meschino W, Cutz E, Chang K, Yonescu R, Batista DA, Chen Y, Chelko S, Crosson JE, Scheel J, Vricella L, Craig BD, Marosy BA, Mohr DW, Hetrick KN, Romm JM, Scott AF, Valle D, Naggert JK, Kwon C, Doheny KF, Judge DP.Mutations in Alstr?m protein impair terminal differentiation of cardiomyocytes. Nat Commun, 2014, 5: 3416. |
| [5] | Dassie F, Favaretto F, Bettini S, Parolin M, Valenti M, Reschke F, Danne T, Vettor R, Milan G, Maffei P. Alstrom syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity. Endocrine, 2021, 71(3): 618-625. |
| [6] | Marshall JD, Bronson RT, Collin GB, Nordstrom AD, Maffei P, Paisey RB, Carey C, Macdermott S, Russell-Eggitt I, Shea SE, Davis J, Beck S, Shatirishvili G, Mihai GM, Hoeltzenbein M, Pozzan GB, Hopkinson I, Sicolo N, Naggert JK, Nishina PM.New Alstr?m syndrome phenotypes based on the evaluation of 182 cases. Arch Intern Med, 2005, 165(6): 675-683. |
| [7] | Collin GB, Marshall JD, Ikeda A, So WV, Russell-Eggitt I, Maffei P, Beck S, Boerkoel CF, Sicolo N, Martin M, Nishina PM, Naggert JK.2 diabetes and neurosensory degeneration in Alstr?m syndrome. Nat Genet, 2002, 31(1): 74-78. |
| [8] | Hearn T, Renforth GL, Spalluto C, Hanley NA, Piper K, Brickwood S, White C, Connolly V, Taylor JFN, Russell-Eggitt I, Bonneau D, Walker M, Wilson DI. Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alstr?m syndrome. Nat Genet, 2002, 31(1): 79-83. |
| [9] | Wang CM, Luo XN, Wang YL, Liu Z, Wu SN, Wang SM, Lan XP, Xu QM, Xu WH, Yuan F, Wang AQ, Zeng FY, Jia J, Chen Y. Novel mutations of the ALMS1 gene in patients with Alstr?m syndrome. Intern Med, 2021, 60(23): 3721-3728. |
| [10] | Hearn T. ALMS1 and Alstr?m syndrome: a recessive form of metabolic, neurosensory and cardiac deficits. J Mol Med (Berl), 2018, 97(1): 1-17. |
| [11] | álvarez-Satta M, Lago-Docampo M, Bea-Mascato B, Solarat C, Castro-Sánchez S, Christensen ST, Valverde D. ALMS 1 regulates TGF-β signaling and morphology of primary cilia. Front Cell Dev Biol, 2021, 9: 623829. |
| [12] | Leitch CC, Lodh S, Prieto-Echagüe V, Badano JL, Zaghloul NA. Basal body proteins regulate notch signaling through endosomal trafficking. J Cell Sci, 2014, 127(Pt 11): 2407-2419. |
| [13] | Zulato E, Favaretto F, Veronese C, Campanaro S, Marshall JD, Romano S, Cabrelle A, Collin GB, Zavan B, Belloni AS, Rampazzo E, Naggert JK, Abatangelo G, Sicolo N, Maffei P, Milan G, Vettor R.ALMS1-deficient fibroblasts over-express extra-cellular matrix components, display cell cycle delay and are resistant to apoptosis. PLoS One, 2011, 6(4): e19081. |
| [14] | Oh EC, Vasanth S, Katsanis N. Metabolic regulation and energy homeostasis through the primary cilium. Cell Metab, 2015, 21(1): 21-31. |
| [15] | Fraser AM, Davey MG. TALPID 3 in Joubert syndrome and related ciliopathy disorders. Curr Opin Genet Dev, 2019, 56: 41-48. |
| [16] | Geets E, Meuwissen MEC, Van Hul W. Clinical, molecular genetics and therapeutic aspects of syndromic obesity. Clin Genet, 2018, 95(1): 23-40. |
| [17] | Gathercole LL, Hazlehurst JM, Armstrong MJ, Crowley R, Boocock S, O'Reilly MW, Round M, Brown R, Bolton S, Cramb R, Newsome PN, Semple RT, Paisey R, Tomlinson JW, Geberhiwot T. Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alstr?m syndrome. Liver Int, 2016, 36(11): 1704-1712. |
| [18] | Girard D, Petrovsky N. Alstr?m syndrome: insights into the pathogenesis of metabolic disorders. Nat Rev Endocrinol, 2010, 7(2): 77-88. |
| [19] | Han JC, Reyes-Capo DP, Liu CY, Reynolds JC, Turkbey E, Turkbey IB, Bryant J, Marshall JD, Naggert JK, Gahl WA, Yanovski JA, Gunay-Aygun M. Comprehensive endocrine-metabolic evaluation of patients with Alstrom syndrome compared with BMI-matched controls. J Clin Endocrinol Metab, 2018, 103(7): 2707-2719. |
| [20] | Romano S, Milan G, Veronese C, Collin GB, Marshall JD, Centobene C, Favaretto F, Dal Pra C, Scarda A, Leandri S, Naggert JK, Maffei P, Vettor R.Regulation of Alstr?m syndrome gene expression during adipogenesis and its relationship with fat cell insulin sensitivity. Int J Mol Med, 2008, 21(6): 731-736. |
| [21] | Huang-Doran I, Semple PK.Knockdown of the Alstr?m syndrome-associated gene Alms1 in 3T3-L1 preadipocytes impairs adipogenesis but has no effect on cell-autonomous insulin action. Int J Obes (Lond), 2010, 34(10): 1554-1558. |
| [22] | Collin GB, Marshall JD, King BL, Milan G, Maffei P, Jagger DJ, Naggert JK.The Alstr?m syndrome protein, ALMS1, interacts with α-Actinin and components of the endosome recycling pathway. PLoS One, 2012, 7(5): e37925. |
| [23] | Favaretto F, Milan G, Collin GB, Marshall JD, Stasi F, Maffei P, Vettor R, Naggert JK. GLUT4 defects in adipose tissue are early signs of metabolic alterations in Alms1GT/ GT, a mouse model for obesity and insulin resistance. PLoS One, 2014, 9(10): e109540. |
| [24] | Nesmith JE, Hostelley TL, Leitch CC, Matern MS, Sethna S, McFarland R, Lodh S, Westlake CJ, Hertzano R, Ahmed ZM, Zaghloul NA. Genomic knockout of alms1 in zebrafish recapitulates Alstr?m syndrome and provides insight into metabolic phenotypes. Hum Mol Genet, 2019. 28(13): 2212-2223. |
| [25] | Geberhiwot T, Baig S, Obringer C, Girard D, Dawson C, Manolopoulos K, Messaddeq N, Bel Lassen P, Clement K, Tomlinson JW, Steeds RP, Dollfus H, Petrovsky N, Marion V. Relative adipose tissue failure in Alstr?m syndrome drives obesity-induced insulin resistance. Diabetes, 2021, 70(2): 364-376. |
| [26] | Bettini S, Bombonato G, Dassie F, Favaretto F, Piffer L, Bizzotto P, Busetto L, Chemello L, Senzolo M, Merkel C, Angeli P, Vettor R, Milan G, Maffei P. Liver fibrosis and steatosis in Alstr?m syndrome: a genetic model for metabolic syndrome. Diagnostics (Basel), 2021, 11(5): 797. |
| [27] | Waldman M, Han JC, Reyes-Capo DP, Bryant J, Carson KA, Turkbey B, Choyke P, Naggert JK, Gahl WA, Marshall JD, Gunay-Aygun M. Alstrom syndrome: renal findings in correlation with obesity, insulin resistance, dyslipidemia and cardiomyopathy in 38 patients prospectively evaluated at the NIH clinical center. Mol Genet Metab, 2018, 125(1-2): 181-191. |
| [28] | Choudhury AR, Munonye I, Sanu KP, Islam N, Gadaga C. A review of Alstr?m syndrome: a rare monogenic ciliopathy. Intractable Rare Dis Res, 2021, 10(4): 257-262. |
| [29] | Poli L, Arroyo G, Garofalo M, Choppin de Janvry E, Intini G, Saracino A, Pretagostini R, Della Pietra F, Berloco PB. Kidney transplantation in Alstr?m syndrome: case report. Transplant Proc, 2017, 49(4): 733-735. |
| [30] | Baig S, Veeranna V, Bolton S, Edwards N, Tomlinson JW, Manolopoulos K, Moran J, Steeds RP, Geberhiwot T. Treatment with PBI-4050 in patients with Alstr?m syndrome: study protocol for a phase 2, single-centre, single-arm, open-label trial. BMC Endocr Disord, 2018, 18(1): 88. |
| [31] | Tahani N, Maffei P, Dollfus H, Paisey R, Valverde D, Milan G, Han JC, Favaretto F, Madathil SC, Dawson C, Armstrong MJ, Warfield AT, Duzenli S, Francomano CA, Gunay-Aygun M, Dassie F, Marion V, Valenti M, Leeson-Beevers K, Chivers A, Steeds R, Barrett T, Geberhiwot T. Consensus clinical management guidelines for Alstr?m syndrome. Orphanet J Rare Dis, 2020, 15(1): 253. |
| [32] | Kaneto H, Obata A, Kimura T, Shimoda M, Okauchi S, Shimo N, Matsuoka TA, Kaku K. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance. J Diabetes, 2017, 9(3): 219-225. |
| [33] | Xu L, Nagata N, Nagashimada M, Zhuge F, Ni YH, Chen GL, Mayoux E, Kaneko S, Ota T. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine, 2017, 20: 137-149. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
